Treatment of murine fusariosis with SCH 56592

Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body we ight/day were studied in immunocompetent mice as therapy for systemic infec tion by Fusarium solani. Treatment was begun 1 h after intravenous infectio n and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 th erapy, with the best results seen at 50 and 100 mg/kg/day. The results at t he highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kglday. SCH 56592 has potential for therapy of systemic infections caused by F. solani.